ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
August 26, 2021RubrYc Therapeutics, Inc. ("RubrYc") and iBio, Inc. ("iBio", NYSEA: IBIO) announced today the closing of RubrYc's Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research. -
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
August 26, 2021iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company" today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., ("RubrYc") for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).
Pharma Sources Insight January 2025
